H.C. Wainwright Reiterates Buy Rating on BioLineRx (BLRX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $26.00 price target on BioLineRx (NASDAQ: BLRX).The analyst commented: "Yesterday ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)